Biological Treatment
We recommend
Good news for sleep in patients with axial spondyloarthritis – ixekizumab effectively reduces night-time back pain
The targeted treatment of axial spondyloarthritis currently relies on the anti-inflammatory effects of tumor necrosis factor (TNF) inhibitors, interleukin IL-17 inhibitors, and Janus kinase (JAK) inhibitors. Besides the objective efficacy of these targeted treatments, it is crucial to describe their influence on subjective symptoms for decision-making in clinical practice. The evaluation of the analgesic effect of ixekizumab (IXE) was provided by the randomized controlled trial COAST-V.
New Therapeutic Options in Light of Current Knowledge on the Pathogenesis of Atopic Dermatitis
Atopic dermatitis (AD) is a chronic inflammatory skin disease characterized by intense itching and…
Alopecia Areata – Autoimmune Inflammatory Disease and a New Targeted Treatment Option
Alopecia areata (AA) is one of the non-scarring focal alopecias. It is an autoimmune disease of the…
Articles on this topic
Is long-term treatment with ixekizumab sufficiently safe?
Psoriasis is a chronic inflammatory disease whose manifestations require long-term treatment.…
Biological treatment of psoriatic arthritis in the 1st line – results of the SPIRIT-H2H study after 1 year of follow-up
The SPIRIT-H2H study compared the efficacy of ixekizumab and adalimumab, either as monotherapy…
Experiences with Long-term Treatment of Psoriasis with Interleukin 17A Inhibitor
The current publication of the long-term extension of the UNCOVER-3 study, which focused on…
Is Baricitinib Suitable for Long-Term Treatment of Rheumatoid Arthritis?
The nature of rheumatoid arthritis requires effective and long-term treatment. The current…
Does Ixekizumab Have Long-term Effects on Improving Psoriatic Arthritis Symptoms?
The extension of the SPIRIT-P2 study brought results of ixekizumab in patients with psoriatic…
View on the Treatment of Rheumatoid Arthritis with Baricitinib Using the NNT Indicator
Clinical parameters assessed by patients themselves are an important tool in evaluating the…
Current Data on the Safety Profile of Baricitinib in the Treatment of Rheumatoid Arthritis
Baricitinib was approved for the treatment of rheumatoid arthritis (RA) in 2017, making it…
Efficacy of Baricitinib in Long-term Therapy of Rheumatoid Arthritis
Baricitinib selectively and reversibly inhibits Janus kinases JAK1 and JAK2 and is used in the…
Ixekizumab is a Safe Option for Long-Term Treatment of Inflammatory Diseases
Psoriasis, psoriatic arthritis (PsA), and axial spondyloarthritis (SpA) are chronic…
Improvement of Joint and Skin Symptoms and Their Contribution to Improving the Quality of Life in Patients with Psoriatic Arthritis
The cause of reduced quality of life in patients with psoriatic arthritis is the involvement…
1
2
Subscribe
Most read on this topic
Journal on this topic
Related topic
Interesting links
Most read on this topic
- Alopecia Areata – Autoimmune Inflammatory Disease and a New Targeted Treatment Option
- Experiences with Long-term Treatment of Psoriasis with Interleukin 17A Inhibitor
- How do IL-17 and IL-23 inhibitors fare in the treatment of psoriasis in direct comparison?
- New Therapeutic Options in Light of Current Knowledge on the Pathogenesis of Atopic Dermatitis
- Biological treatment of psoriatic arthritis in the 1st line – results of the SPIRIT-H2H study after 1 year of follow-up
- Improvement of Joint and Skin Symptoms and Their Contribution to Improving the Quality of Life in Patients with Psoriatic Arthritis
Journal on this topic
Related topic
Interesting links